StockNews.AI
AMIX
StockNews.AI
97 days

Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event

1. Autonomix will present at the Virtual Investor Closing Bell on May 22, 2025. 2. CEO Brad Hauser will discuss innovative catheter-based microchip technology. 3. Their technology may revolutionize treatment for nervous system diseases. 4. Initial focus is on treating pain for pancreatic cancer. 5. The technology is still investigational, not yet cleared for marketing.

4m saved
Insight
Article

FAQ

Why Bullish?

The presentation showcases advanced technology that could attract investor interest. Historical examples show that investor awareness often positively impacts stock performance.

How important is it?

The event has the potential to clarify technology capabilities, which could impact stock prices positively. Increased awareness may lead to greater investor engagement.

Why Short Term?

Immediate interest may arise from the presentation, but long-term impact depends on regulatory approval and market acceptance.

Related Companies

MDGLAVNSGLMD
Live webcast followed by an interactive Q&A session on Thursday, May 22nd at 4:00 PM ET Access the event here THE WOODLANDS, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it will participate in the Virtual Investor Closing Bell Series on Thursday, May 22, 2025 at 4:00 PM ET. As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, will provide a corporate overview and discuss the Company’s first-in-class platform system technology, a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. In addition, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. The live video webcast will be available on the Events page under the Investors section of the Company’s website (autonomix.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook. Investor and Media Contact JTC Team, LLCJenene Thomas (908) 824-0775autonomix@jtcir.com

Related News